Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the SAG gene.
Features include: Nyctalopia, Pigmentary retinopathy, Visual impairment, and Rod-cone dystrophy and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Pigmentary retinopathy, Visual impairment |
Muscles | 1 | Chorioretinal atrophy |
SAG function has not been fully characterized.
Retinitis pigmentosa 47 is associated with mutations in the SAG gene on chromosome 2.
Genetic testing for SAG is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 47 has been reported in the published literature.
No clinical trials have been registered for retinitis pigmentosa 47.
71 publications have been identified in PubMed for retinitis pigmentosa 47. Research spans Case Report / Case Series (23%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 23% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:31 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
13 |
18% |
Disease patterns and progression | 13 | 18% |
Laboratory research | 11 | 15% |
Testing and diagnosis research | 7 | 10% |
New treatment approaches | 7 | 10% |
Clinical study results | 4 | 6% |
Karuntu JS (2026). [PMID: 40530429](https://pubmed.ncbi.nlm.nih.gov/40530429/). *Acta Ophthalmol*. [Clinical Trial Publication]
Chen V (2026). [PMID: 41534910](https://pubmed.ncbi.nlm.nih.gov/41534910/). *Ophthalmic Genet*. [Case Report / Case Series]
Kadyshev VV (2026). [PMID: 41847811](https://pubmed.ncbi.nlm.nih.gov/41847811/). *Vestn Oftalmol*. [Epidemiology / Natural History]
Na H (2026). [PMID: 42256003](https://pubmed.ncbi.nlm.nih.gov/42256003/). *Ophthalmol Sci*. [Basic Science / Preclinical]
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Epidemiology / Natural History]
Gregory-Evans CY (2026). [PMID: 41290216](https://pubmed.ncbi.nlm.nih.gov/41290216/). *Ophthalmic Genet*. [Case Report / Case Series]
Domoto A (2026). [PMID: 41403104](https://pubmed.ncbi.nlm.nih.gov/41403104/). *Ophthalmic Genet*. [Case Report / Case Series]
Wijn DH (2026). [PMID: 41729786](https://pubmed.ncbi.nlm.nih.gov/41729786/). *Otol Neurotol*. [Epidemiology / Natural History]
Romo-Aguas JC (2026). [PMID: 42022048](https://pubmed.ncbi.nlm.nih.gov/42022048/). *Ophthalmol Sci*. [Epidemiology / Natural History]
Abraham JR (2026). [PMID: 41265400](https://pubmed.ncbi.nlm.nih.gov/41265400/). *Ophthalmic Genet*. [Case Report / Case Series]